Atea Pharmaceuticals (AVIR) Accumulated Expenses (2019 - 2026)

Atea Pharmaceuticals' Accumulated Expenses history runs 8 years deep, the most recent figure standing at $2.3 million for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 20.15% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at $2.3 million (down 20.15% YoY), while the FY2025 annual figure was $6.4 million, up 9.04% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $2.3 million, down from $6.4 million in the prior quarter.
• The five-year high for Accumulated Expenses was $20.4 million in Q2 2024, with the low at $1.9 million in Q1 2022.
• The 5-year median for Accumulated Expenses is $10.9 million (2023), against an average of $10.7 million.
• The sharpest annual moves came in 2022 and 2023: Accumulated Expenses sank 91.53% in 2022, then surged 471.11% in 2023.
• Atea Pharmaceuticals' Accumulated Expenses stood at $15.2 million in 2022, then slumped by 62.54% to $5.7 million in 2023, then climbed by 3.65% to $5.9 million in 2024, then gained by 9.04% to $6.4 million in 2025, then tumbled by 64.68% to $2.3 million in 2026.
• Business Quant data shows AVIR's Accumulated Expenses at $2.3 million in Q1 2026, $6.4 million in Q4 2025, and $15.8 million in Q3 2025.